Pulmatrix (PULM)
NASDAQ:PULM
PULM Stock Chart & Stats
$2.35
-$0.25(-3.99%)
At close: 4:00 PM EST
$2.35
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.41 - $9.37
Previous CloseN/A
Volume31.27K
Average Volume (3M)7.19K
Market Cap
$5.51M
Enterprise Value$1.43M
Total Cash (Recent Filing)$4.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.24
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Zero Debt Capital StructureHaving no reported debt materially reduces solvency pressure for a pre-revenue biotech. Without interest or principal service requirements the company retains flexibility to pursue clinical programs, restructurings or M&A while relying on equity financings rather than fixed obligations.
Established Inhaled Therapy PipelinePulmatrix’s inhalation formulation platform and multiple clinical-stage programs provide durable technical differentiation and optionality. Phase-ready assets and a partner-advanced Phase 3 program create multiple development or licensing pathways that can generate sustained value beyond short-term financing events.
Definitive Merger And $19M FinancingThe announced merger and committed $19M financing represent a structural pivot that brings fresh capital and a new combined asset base. This financing materially improves near-term development funding and supports advancing Eos’s MitoXcel programs, reducing immediate reliance on small ad hoc raises.
Bears Say
Near-zero TTM RevenueThe collapse to effectively zero trailing revenue and sustained net losses indicate the business is not generating operating cash and remains pre-commercial. That structural absence of product revenue increases dependence on external capital and makes long-term R&D funding and commercial scaling contingent on financing or deals.
Persistent Negative Operating Cash FlowOngoing negative operating and free cash flow create recurrent funding needs and make the company highly dependent on external financings or transactions. Even with improving burn, sustained negative cash flow constrains strategic optionality and increases dilution risk if capital markets are unfavorable.
Failed Prior Reverse‑merger ExecutionThe terminated Cullgen reverse-merger evidences execution and regulatory risk in the company’s disclosed path to recapitalization. Reliance on reverse-merger deals for financing or a strategic reset raises the chance of delays, uncertainty and repeated transaction failures that can erode stakeholder value.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.41 and its highest was $9.37 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $5.51M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is May 08, 2026 which is in 42 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on Feb 26, 2026. The company reported -$0.254 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.254.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.254 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.346%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.85% Mutual Funds
0.56% Other Institutional Investors
96.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---